ADBiotech Co Ltd

ADBiotech's capital structure shows a debt-to-equity ratio of 1.14, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.66, suggesting potential challenges in meeting short-term obligations. Free cash flow is negative at -2.77 billion KRW, and operating cash flow is also negative at -1.32 billion KRW, reflecting ongoing cash outflows from operations. Profitability metrics are negative, with a return on equity of -21.56% and a return on assets of -6.83%, both significantly below industry norms for pharmaceutical companies. The company reported a net loss of 3.3 billion KRW and an operating loss of 5.0 billion KRW, indicating a challenging operating environment. The company operates through two segments: Veterinary Medicine and Supplementary Feed. The Veterinary Medicine segment focuses on antibiotics, anticoccidial agents, and antimicrobial agents, while the Supplementary Feed segment deals with functional supplementary feeds. Revenue concentration data is not available, but the dual-segment model suggests diversification within the animal health and feed markets. Growth trajectory is negative, with the company reporting a net loss and declining cash flows. No specific revenue growth rates are provided, but the negative operating and free cash flows suggest a contraction in business performance. The company's capital expenditures were -377.68 million KRW, indicating a reduction in investment in physical assets. Risk factors include liquidity constraints and a high debt load. The company's net cash position is negative after subtracting total debt, raising concerns about its ability to service obligations. Dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. Recent events include the latest financial filing, which shows a continued decline in profitability and liquidity. No recent transcripts or filings beyond the financial snapshot are available for further analysis.